Abstract
Nerve injury results in neuropathic pain, a debilitating pain condition. Whereas cannabinoids are consistently shown to attenuate neuropathic pain, the efficacy of opioids is highly controversial. Molecular mechanisms underlying analgesic effects of opioids and cannabinoids are not fully understood. We have shown that the signaling molecule ERK (extracellular signal-regulated kinase) is activated by C-fiber stimulation in dorsal horn neurons and contributes to pain sensitization. In this study, we examined whether opioids and cannabinoids can affect C-fiber-induced ERK phosphorylation (pERK) in dorsal horn neurons in spinal cord slices from normal and spinal nerve-ligated rats. In normal control spinal slices, capsaicin induced a drastic pERK expression in superficial dorsal horn neurons, which was suppressed by morphine (10 μM), the selective μ-opioid receptor agonist DAMGO [[d-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (1 μM)], and the selective CB1 receptor ACEA agonist [arachidonyl-2′-chloroethylamide (5 μM)]. One week after spinal nerve ligation when neuropathic pain is fully developed, capsaicin induced less pERK expression in the injured L5-spinal segment. This pERK induction was not suppressed by morphine (10 μM) and DAMGO (1 μM) but was enhanced by high concentration of DAMGO (5 μM). In contrast, ACEA (10 μM) was still very effective in inhibiting capsaicin-induced pERK expression. In the adjacent L4 spinal segment, both DAMGO and ACEA significantly suppressed pERK induction by capsaicin. These results indicate that, after nerve injury, opioids lose their capability to suppress C-fiber-induced spinal neuron activation in the injured L5 but not in the intact L4 spinal segment, whereas cannabinoids still maintain their efficacy.
Footnotes
-
This study was supported by National Institutes of Health Grants NS40698 and TW7180 (to R.R.J.).
-
doi:10.1124/jpet.105.093583.
-
ABBREVIATIONS: MOR, μ-opioid receptor; ACEA, arachidonyl-2′-chloroethylamide; ANOVA, analysis of variance; CB1, cannabinoid receptor subtype-1; CB2, cannabinoid receptor subtype-2; CCK, cholecystokinin; DAMGO, [d-Ala2, N-Me-Phe4,Gly5-ol]-enkephalin; DRG, dorsal root ganglion; ERK, extracellular signal-regulated kinase; pERK, phosphorylated ERK; IR, immunoreactive; MAPK, mitogen-activated protein kinase; SNL, spinal nerve ligation; TRPV1, transient receptor potential subtype-1.
- Received July 31, 2005.
- Accepted October 11, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|